论文部分内容阅读
目的:探讨门冬胰岛素30联合二甲双胍治疗2型糖尿病的临床效果。方法:68例2型糖尿病患者随机分为对照组(n=34)和观察组(n=34)。对照组皮下注射门冬胰岛素30治疗;观察组在对照组基础上加用二甲双胍片治疗。两组均以6周为1个疗程,连续治疗2个疗程。观察比较两组血糖、血脂、血液流变学等各项指标变化,比较两组体质量(BMI)、血糖达标时间和药品不良反应的差异。结果:治疗后,两组FPG、HbA1c、2hPG,以及血浆黏度、全血黏度及血小板黏附率等指标均较治疗前显著降低(P<0.05),且观察组低于对照组(P<0.05)。两组治疗后TC、TG、LDL-C均较治疗前显著降低(P<0.05);且治疗后观察组TC、TG明显低于对照组(P<0.05);两组HDL-C、BMI治疗前后差异不明显(P>0.05)。观察组血糖达标时间明显短于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:门冬胰岛素30联合二甲双胍治疗2型糖尿病能更有效地控制血糖,明显改善患者糖代谢,减少血糖达标时间,改善患者血脂与血液流变学指标,值得进一步推广应用。
Objective: To investigate the clinical efficacy of insulin aspart 30 combined with metformin in type 2 diabetes mellitus. Methods: Sixty-eight patients with type 2 diabetes were randomly divided into control group (n = 34) and observation group (n = 34). Control group subcutaneous injection of insulin aspart 30 treatment; observation group in the control group based on the use of metformin tablets treatment. Both groups were 6 weeks for a course of treatment, continuous treatment of 2 courses. The changes of blood glucose, blood lipids and hemorheology were observed and compared between the two groups. The differences of body mass index (BMI), blood glucose compliance time and adverse drug reactions between the two groups were compared. Results: After treatment, the indexes of FPG, HbA1c, 2hPG, plasma viscosity, whole blood viscosity and platelet adhesion rate of two groups were significantly lower than those before treatment (P <0.05), and the observation group was lower than the control group (P <0.05) . The levels of TC, TG and LDL-C in both groups after treatment were significantly lower than those before treatment (P <0.05). After treatment, the levels of TC and TG in the observation group were significantly lower than those in the control group (P <0.05) Before and after the difference was not significant (P> 0.05). Observation group blood glucose compliance time was significantly shorter than the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: Aspart 30 combined with metformin in type 2 diabetes can control blood sugar more effectively, improve glucose metabolism, reduce blood glucose compliance time and improve blood lipid and hemorheology indexes of patients, which is worth to be further popularized.